Panelists to discuss best practices in commercialization of regenerative medicine products
Westport, CT, March 30, 2010 – Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Senior Vice President Dean Tozer will participate on a panel at the inaugural 2010 Translational Regenerative Medicine Forum to be held April 6 – 8, 2010, at the Benton Convention Center in Winston-Salem, N.C.
Mr. Tozer will take part in a panel discussion titled, “Best Practices in Commercialization” on Thursday, April 8, 2010, at 8:30 a.m. EST. Joining Tozer will be moderator R. Lee Buckler, BEd, LLB, Founder, Managing Director, and Principal Consultant of the Cell Therapy Group; Anthony Caggiano, MD, PhD, Vice President, Preclinical Development of Acorda Therapeutics; Ed Field, President and Chief Operating Officer of Aldagen; Robert Deans, PhD, Senior Vice President, Regenerative Medicine of Athersys; and Richard S. Stack, MD, FACC, President of Synecor.
The panel will explore the unique challenges of commercializing regenerative medicine products and will draw on the participants’ real-world experiences to provide best practices for how companies can successfully implement a commercialization strategy.
“Striking the right balance of resource allocation between product development and commercialization within rapidly growing companies is always a challenge,” said Tozer. “This challenge is magnified in the field of regenerative medicine because both the research and commercial efforts must be innovative, successfully executed, and also educate government agencies, health care providers and patients along the way. ABH has achieved consistent, double-digit revenue growth by addressing and overcoming commercialization challenges for our lead product, Dermagraft®, and I look forward to sharing how we faced them head on to become a leader in our field.”
ABH will also present a poster abstract titled, “Fibroblast-Based Tissue-Engineered Products for Regenerative Medicine Applications.” The abstract will summarize the composition of Dermagraft and describe how the product constituents may be involved in potential mechanisms of action that could support various clinical applications. The poster will be available for viewing at the Forum.
The Forum serves to inspire interactions between leaders in academic and clinical research, biotechnology, regulatory and healthcare policy.
For more information visit www.regenerativemedicinefoundation.org and to register for the meeting, please visit www.rmconferences.org.
About Advanced BioHealing, Inc.
Advanced BioHealing develops and commercializes living cell therapies that repair damaged human tissue and enable the body to heal itself. A privately held company with more than 250 employees, Advanced BioHealing maintains its corporate office in Westport, Conn., a 70,000 sq. ft. manufacturing facility in La Jolla, Calif., and a research facility in Nashville, Tenn. To meet Advanced BioHealing’s executives and learn more about the Company, please visit the Company’s web site at www.ABH.com.
About Dermagraft®
Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process. It is FDA approved to treat diabetic foot ulcers and is the focus of an ongoing pivotal trial in subjects with venous leg ulcers (VLUs) to assess the product’s safety and efficacy in the promotion of healing VLUs. To date, nearly 200,000 applications of Dermagraft have been administered in over 1,000 wound care centers and outpatient clinics nationwide. For videos of Dermagraft in action, case studies, research and more, visit www.Dermagraft.com.